Gå direkt till huvudinnehållet

Cerebral pares

Senast uppdaterad: Publicerad:
Sakkunnig:
  1. Rosenbaum P. Cerebral palsy: what parents and doctors want to know. BMJ 2003; 326: 970-4. PubMed  
  2. Koman LA, Smith BP, Shilt JS. Cerebral palsy. Lancet 2004; 363: 1619-31. PubMed  
  3. Krigger KW. Cerebral palsy: An overview. Am Fam Physician 2006; 73: 91-100. PubMed  
  4. Cerebral palsy. Colver A, Fairhurst C, Pharoah PO. Lancet. 2014 Apr 5;383(9924):1240-9. doi: 10.1016/S0140-6736(13)61835-8. DOI  
  5. Mutch LW, Alberman E, Hagberg B, Kodama K, Velickovic MV. Cerebral palsy epidemiology: where are we now and where are we going? Dev Med Child Neurol 1992; 34: 547-555. PubMed  
  6. Kennes J, Rosenbaum P, Hanna SE, Walter S, Russell D, Raina P, et al. Health status of school-aged children with cerebral palsy: information from a population-based sample. Dev Med Child Neurol 2002; 44: 240-247. PubMed  
  7. Lie KK, Grøholt E-K, Eskild A. Association of cerebral palsy with Apgar score in low and normal birthweight infants: population bassed cohort study. BMJ 2010; 341: c4990. BMJ (DOI)  
  8. Boyle CA, Yeargin-Allsopp M, Doernberg NS, Holmgreen P, Murphy CC, Schendel DE. Prevalence of selected developmental disabilities in children 3-10 years of age: the Metropolitan Atlanta Developmental Disabilities Surveillance Program, 1991. Morb Mortal Wkly Rep CDC Surveill Summ 1996; 45: 1-14. PubMed  
  9. Regionalt vårdprogram, Cerebral pares hos barn och ungdom, Stockholms läns landsting www.neuropediatrik.blf.net/vardprogram/cp.pdf
  10. Himmelmann K, Hagberg G, Beckung E, Hagberg B, Uvebrant P. The changing panorama of cerebral palsy in Sweden IX. Prevalence and origin in the birth-year period 1995-1998. Acta Paediatr 2005;94:287-94 PubMed  
  11. Himmelmann K, Beckung E, Hagberg G, Uvebrant P. Gross and fine motor function and accompanying impairments in cerebral palsy. Dev Med Child Neurol. 2006 Jun;48(6):417-23 PubMed  
  12. Nordmark E, Hägglund G, Lagergren J. Cerebral palsy in southern Sweden II. Gross motor function and disabilities. Acta Paediatr 2001;90:1277-82 PubMed  
  13. Moster D, Wilcox AJ, Vollset SE, Markestad T, Lie RT. Cerebral palsy among term and postterm births. JAMA 2010; 304: 976-82. Journal of the American Medical Association  
  14. Stanley FJ, Blair E, Alberman E. Cerebral palsies: epidemiology and causal pathways. London: Mac Keith, 2000.
  15. Escobar GJ, Littenberg B, Petitti DB. Outcome among surviving very low birthweight infants: a meta-analysis. Arch Dis Child 1991; 66: 204-211. PubMed  
  16. Nelson KB, Ellenberg JH. Childhood neurological disorders in twins. Paediatr Perinat Epidemiol 1995; 9: 135-145. PubMed  
  17. Bass N. Cerebral palsy and neurodegenerative disease. Curr Opin Pediatr 1999; 11: 504-7. PubMed  
  18. Du Plessis AJ, Volpe JJ. Perinatal brain injury in the preterm and term newborn. Curr Opin Neurol 2002; 15: 151-157. PubMed  
  19. Cans C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 2000; 42: 816-824. PubMed  
  20. Nelson KB. What proportion of cerebral palsy is related to birth asphyxia? J Pediatr 1988; 112: 572-574. PubMed  
  21. Flett PJ. Rehabilitation of spasticity and related problems in childhood cerebral palsy. J Paediatr Child Health 2003; 39: 6-14. PubMed  
  22. Essex C. Hyperbaric oxygen and cerebral palsy: no proven benefit and potentially harmful. Dev Med Child Neurol 2003; 45: 213-15. PubMed  
  23. Nelson KB, Grether JK. Causes of cerebral palsy. Curr Opin Pediatr 1999; 11: 487-91. PubMed  
  24. Nelson KB, Willoughby RE. Infection, inflammation and the risk of cerebral palsy. Curr Opin Neurol 2000; 13: 133-39. PubMed  
  25. Jarvis S, Glinianaia SV, Torrioli M-G, et al. Cerebral palsy and intrauterine growth in single births: European collaborative study. Lancet 2003; 362: 1106-11. PubMed  
  26. Palisano RJ, Rosenbaum PL, Walter SD, Russell DJ, Wood EP, Galuppi BE. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997; 39: 214-223. PubMed  
  27. Cadman D, Boyle M, Szatmari P, Offord DR. Chronic illness, disability, and mental and social well-being: findings of the Ontario child health study. Pediatrics 1987; 79: 805-813. Pediatrics  
  28. Yude C, Goodman R. Peer problems of 9-11-year-old children with hemiplegia in mainstream school: can these be predicted? Dev Med Child Neurol 1999; 41: 4-8. PubMed  
  29. Boyle CA, Decoufle P, Yeargin-Allsopp M. Prevalence and health impact of developmental disabilities in US children. Pediatrics 1994; 93: 399-403. Pediatrics  
  30. Evans P, Elliott M, Alberman E, Evans S. Prevalence and disabilities in 4 to 8 year olds with cerebral palsy. Arch Dis Child 1985; 60: 940-45. PubMed  
  31. Beckung E, Hagberg G. Neuroimpairments, activity limitations, and participation restrictions in children with cerebral palsy. Dev Med Child Neurol 2002; 44: 309-16. PubMed  
  32. Roijen LE, Postema K, Limbeek VJ, Kuppevelt VH. Development of bladder control in children and adolescents with cerebral palsy. Dev Med Child Neurol 2001; 43: 103-07.
  33. Lofterød B, Terjesen T, Skaaret I. Ganganalyse - nytt diagnostisk hjelpemiddel. Tidsskr Nor Lægeforen 2005; 125: 2014-6. PubMed  
  34. CPUP uppföljningsprogram för cerebral pares: http://www.cpup.se/se/index.php
  35. Hägglund G, Andersson S, Düppe H, Lauge-Pedersen H, Nordmark E, Westbom L. Prevention of dislocation of the hip in children with cerebral palsy. The first ten years of a populationbased prevention programme. J Bone Joint Surg Br. 2005 Jan; 87(1):95-101 PubMed  
  36. Hägglund G, Andersson S, Düppe H, Lauge-Pedersen H, Nordmark E, Westbom L. Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity. J Pediatr Orthop B. 2005 Jul; 14(4):269-73 PubMed  
  37. Hoare B, et al. Rationale for using botulinum toxin A as an adjunct to upper limb rehabilitation in children with cerebral palsy. J Child Neurol. 2014 Aug;29(8):1066-76. PubMed  
  38. Wong V. Evidence-based approach of the use of botulinum toxin type A (BTX) in cerebral palsy. Pediatr Rehabil 2003; 6: 85-96. PubMed  
  39. Ade-Hall RA, Moore AP. Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. Cochrane Database Syst Rev 2000; 2: CD001408. Cochrane (DOI)  
  40. Wasiak J, Hoare B, Wallen M. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev 2004; 4: CD003469. Cochrane (DOI)  
  41. Russo RN, Crotty M, Miller MD, Murchland S, Flett P, Haan E. Upper-limb botulinum toxin a injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: a single-blind, randomized, controlled trial. Pediatrics 2007; 119: 1149-58. Pediatrics  
  42. Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review). Neurology 2010; 74: 336-43. Neurology  
  43. Myrhaug HT, Østensjø S, Lerdal B et al. Intensiv trening/habilitering til barn med medfødt og ervervet hjerneskade. Rapport fra kunnskapssenteret nr 27, 2008.
  44. Ryan JM, Cassidy EE, Noorduyn SG, O'Connell NE. Exercise interventions for cerebral palsy. Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No.: CD011660. DOI: 10.1002/14651858.CD011660.pub2 DOI  
  45. McLaughlin J, Bjornson K, Temkin N, Steinbok P, Wright V, Reiner A, et al. Selective dorsal rhizotomy: meta-analysis of three randomised controlled trials. Dev Med Child Neurol 2002; 44: 17-25. PubMed  
  46. McLaughlin J, Bjornson K, Temkin N, Steinbok P, Wright V, Reiner A, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol 2002; 44: 17-25. PubMed  
  47. Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM treatment outcomes committee review panel. Dev Med Child Neurol 2000; 42: 634-645. PubMed  
  48. Butler C. Augmentative mobility: why do it? In: KM Jaffe, ed. Phys Med Rehabil Clin N Am 1991; 2: 801-816. PubMed  
  49. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD004661. DOI: 10.1002/14651858.CD004661.pub3. DOI  
  50. Strauss D, Shavelle R. Life expectancy of adults with cerebral palsy. Dev Med Child Neurol 1998; 40: 369-75. PubMed  
  51. Hutton JL, Pharoah PO. Effects of cognitive, motor, and sensory disabilities on survival in cerebral palsy. Arch Dis Child 2002; 86: 84-89. PubMed  
  52. Sillanpää M, Shinnar S. Long-term mortality in childhood-onset epilepsy. N Engl J Med 2010; 363: 2522-9. PubMed  
  53. Ramstad K, Blom US. Barn med cerebral parese henvist til en tverrfaglig habiliteringsenhet. Tidsskr Nor Lægeforen 2004; 124: 1235-6. PubMed  
  54. Edgar TS. Clinical utility of botulinum toxin in the treatment of cerebral palsy: a comprehensive review. J Child Neurol 2001; 16: 37-46. PubMed  
  • Martin Jägervall, överläkare, Barn- och ungdomskliniken, Centrallasarettet Växjö

Tidigare sakkunniga

  • Stein E Høyer, överläkare, barneavdelingen, Regionsykehuset i Tromsø
  • Gisle Roksund, specialist i allmänmedicin och samhällsmedicin, Klyve legesenter, Skien
  • Ingard Løge, specialist inom allmänmedicin, Institutt for samfunnsmedisinske fag, Norges teknisk-naturvitenskapelige universitet, Trondheim
  • Kurt Østhuus Krogh, specialist inom barnsjukdomar, barne- og ungdomsklinikken, St. Olavs Hospital, Trondheim